The 11 patients had already received treatment after treatment for their cancers, some as many as 20 different courses of therapy. Yet their myelomas, almost all classified by doctors as “high risk,” kept coming back. Their options faded away. Then they joined a clinical trial to be the first people ever to receive a new experimental, immune-harnessing...Continue Reading